The country paused its rollout of the Oxford-AstraZeneca vaccine after preliminary trial data showed it offered minimal protection against mild to moderate illness caused by the variant...
The country paused its rollout of the Oxford-AstraZeneca vaccine after preliminary trial data showed it offered minimal protection against mild to moderate illness caused by the variant...